References
- Chanan-Khan A A, Niesvizky R, Hohl R J, Zimmerman T M, Christiansen N P, Schiller G J, et al. Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma 2009; 50: 559–565
- Stephens A C, Rivers R P. Antisense oligonucleotide therapy in cancer. Curr Opin Mol Ther 2003; 5: 118–122
- Tamm I, Dorken B, Hartmann G. Antisense therapy in oncology: new hope for an old idea?. Lancet 2001; 358: 489–497
- Cory S, Huang D C, Adams J M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22: 8590–8607
- Klasa R J, Gillum A M, Klem R E, Frankel S R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002; 12: 193–213
- Frankel S R. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis. Semin Oncol 2003; 30: 300–304
- van de Donk N W, de Weerdt O, Veth G, Eurelings M, van Stralen E, Frankel S R, et al. G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Leukemia 2004; 18: 1078–1084
- Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 2008; 143: 355–360